Blood Stream Infection Testing Market Overview
As per Econ Market Research analysis, the Global Blood Stream Infection Testing Market was estimated at US$ 7.11 Billion in 2026 and is forecast to attain US$ 21.7 Billion by 2035, expanding at a CAGR of 13.2% between 2026 and 2035. The base year for the study is 2025.
Since its establishment, the blood stream infection testing market has experienced substantial expansion and innovation. Because it is essential to the diagnosis and treatment of potentially fatal bloodstream infections, this field has grown in importance over the years within the healthcare sector. Pathogens including bacteria, viruses, and fungi enter the circulation and cause these infections, which can result in sepsis or other catastrophic illnesses.
A variety of diagnostic methods, including as blood cultures, molecular tests, and biomarker analysis, are used in blood stream infection testing in order to pinpoint and define the causing agents. Technological developments, enhanced diagnostic precision, and a rising understanding of the significance of early and precise diagnosis have propelled the market',s progress. In an effort to improve patient care and lower the prevalence of illnesses linked to healthcare, healthcare practitioners have been using these testing techniques more and more.
The COVID-19 epidemic also brought attention to the need for quick and accurate diagnostic technologies, which fueled the market',s expansion. As new diagnostic modalities, point-of-care testing, and advanced automation further improve the efficiency and effectiveness of detecting and managing bloodstream infections, ultimately benefiting patients and healthcare systems worldwide, it is anticipated that the blood stream infection testing market will continue to grow in the years to come.
Market Dynamics
The market for blood stream infection testing is dynamic and ever-changing, influenced by a multitude of factors. The rising prevalence of bloodstream infections, especially in hospital settings, is one of the main factors propelling the market',s expansion. Due to the potentially fatal nature of these illnesses, there is an increasing need for precise and timely diagnostic services. Technological developments in diagnostics have had a big impact on market dynamics.
Enhanced sensitivity and specificity of molecular diagnostic tools, such as polymerase chain reaction (PCR) and sequencing approaches, facilitate the early identification of bacteria causing bloodstream infections. Furthermore, point-of-care testing and automation have become more popular, enabling faster turnaround times and lessening the strain on clinical laboratories. The COVID-19 pandemic and other continuing global health crises have brought attention to the significance of effective diagnostic instruments.
The pandemic spurred advancements in diagnostic testing research and development, resulting in modifications and breakthroughs that can also help blood stream infection testing. Reimbursement policies, economic variables, and regulatory changes also impact market dynamics. The increasing prevalence of collaboration among industrial participants, academic establishments, and healthcare facilities has promoted innovation and the launch of novel products and technology. The market for blood stream infection testing is defined by a dynamic regulatory and economic environment, rising demand, and technical improvements. Together, these elements support the market',s ongoing expansion and development, which is centered on enhancing patient outcomes and the effectiveness of the healthcare system.
Market Drivers
Rising Incidence of Bloodstream Infections
Bloodstream infections, which are commonly referred to as sepsis, are dangerous illnesses with a high risk of death that are caused by organisms such as bacteria, viruses, or fungi. Numerous variables, such as surgical operations, medical gadgets, immunocompromised patients, and antibiotic-resistant strains of bacteria, can lead to these infections. There is an increasing need for precise and quick diagnostic techniques to identify and treat community-acquired diseases and illnesses linked to healthcare as these conditions continue to rise.
Bloodstream infections have serious consequences that can include longer hospital admissions, higher healthcare expenses, and, most importantly, higher death rates if they are not treated promptly and effectively. There is a high demand for blood stream infection testing solutions as a result of healthcare practitioners prioritizing early identification and treatment due to the increasing occurrence of these illnesses. This in turn stimulates the field',s research and development efforts, leading to the creation of innovative diagnostic techniques and technologies that can provide a faster and more accurate identification of the microorganisms causing the illness. Because blood stream infection testing is essential to enhancing patient outcomes and lessening the strain on global healthcare systems, the market for these tests is consequently still growing.
Increased Awareness and Focus on Healthcare-Associated Infections (HAIs)
Healthcare-associated infections (HAIs) are infections that patients contract while receiving medical care in hospitals or other healthcare facilities. The healthcare industry is increasingly concerned about HAIs. Urinary tract infections, bloodstream infections, surgical site infections, and other infections are examples of these infections. In addition to causing patient morbidity and death, HAIs cost healthcare systems a great deal of money.
The influence that healthcare-associated infections (HAIs) have on patient safety and costs has been increasingly recognized, which has LED to a focus on avoiding, identifying, and controlling these infections. Given their potential severity and implications, bloodstream infections are especially concerning. In order to reduce the dangers connected with healthcare-associated infections (HAIs), particularly bloodstream infections, healthcare providers and institutions are putting more emphasis on early identification and intervention. This shift in mindset has spurred the adoption of blood stream infection testing methods as a critical component of infection control and prevention strategies.
Restraints:
Limited Access to Advanced Healthcare Facilities
Remote or rural locations frequently lack access to cutting-edge medical facilities, such as labs with cutting-edge diagnostic equipment. Patients can find it more difficult to get fast and accurate blood stream infection tests due to the physical distance to such facilities. The establishment and upkeep of diagnostic facilities can be difficult in developing regions due to insufficient roads, transportation, and electricity, which further restricts access to testing.
In resource-constrained places, the provision of blood stream infection testing services can be hampered by a lack of qualified laboratory personnel, medical experts, and necessary medical equipment. These areas can have limited financial resources, which can limit investments in cutting-edge diagnostic technologies and make it challenging to provide accurate and reasonably priced blood stream infection testing services. Testing utilization can be further hampered by limited access to healthcare facilities, which can also result in a decreased understanding of the significance of early identification and treatment of bloodstream infections among patients and healthcare professionals.
High Initial Setup and Ongoing Maintenance Costs
A significant initial capital expenditure is frequently needed to acquire and set up sophisticated blood stream infection testing infrastructure and equipment. Smaller healthcare facilities and areas with limited resources can be discouraged from implementing these technologies due to the associated costs. The continuous expenses of operation and maintenance, such as staff training, reagent procurement, and equipment calibration, might put a pressure on healthcare providers', finances after the initial setup. It might be especially difficult for schools with tight funds to cover these expenses.
Specialized knowledge is required to manage and maintain complex blood stream infection testing equipment. It is imperative that laboratory personnel have ongoing training, which comes with extra costs. This problem can get much more complicated due to the lack of qualified workers. Financial limitations could also result in unequal access to cutting-edge diagnostic technology, larger, better-funded healthcare facilities are more likely to provide comprehensive blood stream infection testing services, whereas the capabilities of smaller facilities can be constrained.
Opportunities:
Development and Adoption of Point-of-Care Testing( POCT) Devices
POCT devices make it possible to test patients right away at the point of care or very close to it, which is essential for promptly diagnosing bloodstream infections. Quick diagnosis allows medical professionals to start the right therapy right away, possibly saving lives. POCT devices provide significantly faster turnaround times by doing away with the requirement to send samples to off-site laboratories and wait for findings. This lowers the chance of consequences from bloodstream infections while also expediting patient care.
Because POCT devices are decentralized, they can be used in a variety of healthcare environments, such as isolated or resource-constrained locations with restricted access to centralized laboratories. With POCT devices, doctors can make quick decisions and treatment decisions without having to wait for laboratory analysis and sample transportation. This streamlines the diagnostic process. Because POCT devices use fewer resources and need less sample processing and transportation, they can often be more affordable than standard centralized testing. By reducing the amount of time patients must wait for findings and enabling prompt care, POCT devices can improve patient satisfaction levels overall.
Telemedicine and Remote Monitoring
By removing distance and enabling people in underserved or distant locations to undergo blood stream infection testing and monitoring, telemedicine helps patients receive healthcare services from the comfort of their homes. Vital signs and other pertinent health data can be continuously tracked via telemedicine platforms and remote monitoring equipment. This makes it possible to identify alterations early on that could point to the existence of a bloodstream infection and allows for prompt action.
Patients can receive routine blood stream infection testing and monitoring outside of clinical settings thanks to telemedicine and remote monitoring, which can lighten the burden on healthcare facilities. This can reduce the number of needless hospital visits and increase the effectiveness of healthcare systems. Patients with chronic conditions who are more likely to develop bloodstream infections benefit greatly from telemedicine and remote monitoring. Overall health outcomes can be enhanced by prompt interventions and routine monitoring. The quick transmission of blood stream infection test results made possible via telemedicine can help medical professionals make well-informed judgments and, if needed, begin the proper therapies.
Segment Overview
By Product
Based on product, the global blood stream infection testing market is divided into instruments, consumables, software and services. The consumables category dominates the market with the largest revenue share in 2022. Consumables form another integral segment, comprising the necessary supplies and reagents used in blood stream infection testing. These include blood culture bottles, testing kits, culture media, and specialized reagents designed to support the diagnostic process.
Software solutions have become increasingly critical in the blood stream infection testing market. They provide data analysis, interpretation, and reporting capabilities, making it easier for healthcare professionals to access and understand test results, streamline workflows, and manage patient information efficiently. Services are an essential component, offering a wide range of support, including installation, maintenance, training, and consulting. Service providers ensure the proper functioning of instruments and the smooth operation of blood stream infection testing processes in healthcare settings.
Instruments play a central role in this market, encompassing a wide range of diagnostic devices and equipment used to perform blood stream infection testing. These instruments include automated blood culture systems, PCR machines, mass spectrometers, and various other cutting-edge technologies that enable the detection and identification of pathogens in blood samples.
By Technique
Based on the technique, the global blood stream infection testing market is categorized into conventional, automated. The automated category leads the global blood stream infection testing market with the largest revenue share in 2022. Automated methods have revolutionized blood stream infection testing by leveraging cutting-edge technologies and equipment. Automated systems, such as blood culture machines, PCR devices, and mass spectrometers, expedite the diagnostic process, delivering faster results with increased accuracy. These methods minimize the risk of contamination, reduce hands-on labor, and often integrate software for more streamlined data analysis and reporting.
Conventional methods involve traditional techniques for blood stream infection testing, such as blood cultures and manual laboratory procedures. These methods have been the historical standard for identifying pathogens in blood samples. While they provide accurate results, conventional approaches often require longer turnaround times, ranging from hours to several days, due to the need for incubation and manual analysis. Additionally, they are labor-intensive and depend heavily on the expertise of laboratory personnel.
By Technology
Based on technology, the global blood stream infection testing market is segmented into culture-based, molecular, proteomic. The culture-based segment dominates the blood stream infection testing market. Culture-based methods are the traditional and well-established approach for identifying bloodstream infections. This category includes blood cultures and various agar-based techniques. Blood culture systems involve incubating blood samples to promote the growth of microorganisms, which are then identified through visual and biochemical analysis.
While culture-based methods provide reliable results, they often require longer turnaround times, typically ranging from hours to several days. Additionally, they can be limited by factors like slow-growing organisms and contamination risks. Molecular methods represent a highly innovative segment in the blood stream infection testing market. These techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification, detect the genetic material of pathogens directly in blood samples.
Molecular methods offer rapid results, high sensitivity, and the ability to detect a wide range of microorganisms, including those that are difficult to culture. Proteomic methods encompass technologies that analyze the proteins produced by pathogens or the host response to infection. Mass spectrometry, for example, can identify specific protein profiles in blood samples that are indicative of bloodstream infections.
By Application
Based on application, the global blood stream infection testing market is divided into bacterial, fungal, mycobacterial. The bacterial category dominates the market with the largest revenue share in 2022. Bacterial blood stream infection testing is primarily focused on the identification of various bacteria in the bloodstream. Bacterial infections are one of the most common causes of bloodstream infections and can encompass a wide spectrum of microorganisms, including both common and less prevalent pathogens. Accurate and rapid detection of these bacteria is crucial for timely intervention and targeted antibiotic therapy to ensure patient recovery.
Fungal blood stream infection testing is specialized in detecting fungal pathogens in the blood, such as Candida and Aspergillus species. Fungal bloodstream infections are often associated with immunocompromised individuals, patients on long-term antibiotics, or those with certain medical conditions. Mycobacterial blood stream infection testing is specifically designed for detecting mycobacterial pathogens, particularly Mycobacterium tuberculosis, which causes tuberculosis. Tuberculosis remains a global health concern, and the identification of mycobacterial infections in the bloodstream is vital for initiating prompt treatment and preventing the spread of the disease.
By End-users
Based on the end-users, the global blood stream infection testing market is categorized into hospitals, independent diagnostics centers, others. The hospitals category leads the global blood stream infection testing market with the largest revenue share in 2022. Hospitals are a primary and central hub for blood stream infection testing. They serve as the frontline in diagnosing and managing a wide range of medical conditions, including bloodstream infections. Hospitals are equipped with comprehensive diagnostic laboratories, specialized equipment, and experienced healthcare professionals, allowing for a prompt and comprehensive approach to testing. They often perform a high volume of tests on both inpatients and outpatients, making them a key player in the blood stream infection testing market.
Independent diagnostics centers are dedicated facilities that specialize in a wide range of diagnostic services, including blood stream infection testing. These centers offer testing services independently of hospital systems and are often chosen for their convenience, efficiency, and specialization. Patients seeking quicker access to specific tests can opt for independent diagnostics centers, which can provide comprehensive blood stream infection testing with a focus on accuracy and rapid results.
Market Overview by Region
The global blood stream infection testing market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific emerged as the leading region, capturing the largest market share in 2022. Asia-Pacific has a sizable population and a wide range of healthcare issues. Due to the high frequency of infectious diseases in the area, particularly bloodstream infections, there is a growing need for sophisticated diagnostic tools to successfully manage these health issues.
Several Asia-Pacific nations have had rapid economic growth, which has raised investments in state-of-the-art medical technologies and increased healthcare spending. This has made it easier for sophisticated blood stream infection testing tools, procedures, and services to be adopted. By building state-of-the-art facilities and investing in healthcare infrastructure, the area is now better equipped to identify and treat infectious diseases, particularly bloodstream infections. As a result of Asia-Pacific',s embracing of technological and scientific developments in medicine, creative blood stream infection detection methods have been created.
Relevant and easily obtainable diagnostic instruments have been developed thanks in large part to the efforts of local manufacturers and researchers. Numerous Asia-Pacific nations have undertaken healthcare reforms and initiatives with the goal of enhancing patient care, infection control, and diagnostic accuracy. The market for blood stream infection testing has expanded in part because of these initiatives spearheaded by the government.
The adoption of testing and diagnostic solutions in the region has been prompted by a greater understanding among the general public and healthcare professionals of the need of early detection and management of bloodstream infections. Infectious illness control has become a primary concern due to the region',s high population density and mobility.
Competitive Landscape
In the global blood stream infection testing market, a few major players exert significant market dominance and have established a strong regional presence. These leading companies remain committed to continuous research and development endeavors and actively engage in strategic growth initiatives, including product development, launches, joint ventures, and partnerships. By pursuing these strategies, these companies aim to strengthen their market position, expand their customer base, and capture a substantial share of the market.
Key Players:
Bruker Corporation
bioMérieux SA
Abbott Laboratories
Becton, Dickinson and Company
Cepheid
Thermo Fisher Scientific Inc.
Accelerate Diagnostics, Inc.
AdvanDx, Inc.
F. Hoffmann-La Roche Ltd.
Luminex Corporation
Danaher Corporation
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
T2 Biosystems, Inc.
Recent Developments
In December 2022, In children and newborns with bloodstream infections, identifying pathogens more quickly. Accurate pathogen identification in small blood samples is sped up by a fast and incredibly effective designed pathogen capture technology that may even save lives.
Blood Stream Infection Testing Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Product |
|
| Technique |
|
| Technology |
|
| Application |
|
Key Players
- bioMérieux
- Becton Dickinson (BD)
- Roche Diagnostics
- Abbott Laboratories
- T2 Biosystems
- Luminex
- Cepheid (Danaher)
Table of Contents
1. GLOBAL BLOOD STREAM INFECTION TESTING MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY PRODUCT (USD MILLION)
- 1.5.1 GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY PRODUCT (2026-2035)
- 1.5.2 INSTRUMENTS
- 1.5.3 CONSUMABLES
- 1.5.4 SOFTWARE AND SERVICES
- 1.6. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY PRODUCT IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY TECHNIQUE (USD MILLION)
- 1.7.1 GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY TECHNIQUE (2026-2035)
- 1.7.2 CONVENTIONAL
- 1.7.3 AUTOMATED
- 1.8. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY TECHNIQUE IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY TECHNOLOGY (USD MILLION)
- 1.9.1 GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY TECHNOLOGY (2026-2035)
- 1.9.2 CULTURE-BASED
- 1.9.3 MOLECULAR
- 1.9.4 PROTEOMIC
- 1.10. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY TECHNOLOGY IN 2026 & 2035
- 1.11. MARKET ANALYSIS BY BY APPLICATION (USD MILLION)
- 1.11.1 GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY APPLICATION (2026-2035)
- 1.11.2 BACTERIAL
- 1.11.3 FUNGAL
- 1.11.4 MYCOBACTERIAL
- 1.12. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY BY APPLICATION IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF BLOOD STREAM INFECTION TESTING MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY BLOOD STREAM INFECTION TESTING MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL BLOOD STREAM INFECTION TESTING MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE BLOOD STREAM INFECTION TESTING MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SEGMENT BY BY PRODUCT, (USD MILLION)
- 13.1. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.2. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.3. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.4. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.5. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.6. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.7. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.8. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.9. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.10. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.11. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.12. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SEGMENT BY BY TECHNIQUE, (USD MILLION)
- 13.13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.14. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
- 13.15. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.16. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
- 13.17. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.18. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
- 13.19. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.20. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
- 13.21. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.22. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
- 13.23. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2022-2029)
- 13.24. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNIQUE (2030-2035)
13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SEGMENT BY BY TECHNOLOGY, (USD MILLION)
- 13.25. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.26. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.27. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.28. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.29. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.30. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.31. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.32. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.33. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.34. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.35. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.36. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SEGMENT BY BY APPLICATION, (USD MILLION)
- 13.37. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.38. GLOBAL BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.39. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.40. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.41. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.42. EUROPE BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.43. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.44. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.45. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.46. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
- 13.47. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2022-2029)
- 13.48. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET AND MARKET SHARE BY BY APPLICATION (2030-2035)
14. COMPANY PROFILES
- 14.1. BIOMÉRIEUX
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. BECTON DICKINSON (BD)
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. ROCHE DIAGNOSTICS
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. ABBOTT LABORATORIES
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. T2 BIOSYSTEMS
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. LUMINEX
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. CEPHEID (DANAHER)
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL BLOOD STREAM INFECTION TESTING MARKET GROWTH RATE BY BY PRODUCT (2026-2035)
- TABLE 3. GLOBAL BLOOD STREAM INFECTION TESTING MARKET GROWTH RATE BY BY TECHNIQUE (2026-2035)
- TABLE 4. GLOBAL BLOOD STREAM INFECTION TESTING MARKET GROWTH RATE BY BY TECHNOLOGY (2026-2035)
- TABLE 5. GLOBAL BLOOD STREAM INFECTION TESTING MARKET GROWTH RATE BY BY APPLICATION (2026-2035)
- TABLE 6. COMPANY'S RANK BY BLOOD STREAM INFECTION TESTING MARKET REVENUE
- TABLE 7. GLOBAL BLOOD STREAM INFECTION TESTING MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 8. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 9. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 10. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 11. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY REGION, (2022-2029)
- TABLE 12. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE BY REGION, (2030-2035)
- TABLE 14. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 15. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 16. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 17. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 18. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 19. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 20. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 21. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 22. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 23. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 24. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 26. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2030-2035)
- TABLE 27. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 28. UNITED STATES BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 29. UNITED STATES BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 30. CANADA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 31. CANADA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 32. MEXICO BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 33. MEXICO BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 34. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 36. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2030-2035)
- TABLE 37. EUROPE BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 38. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 39. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 40. GERMANY BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 41. GERMANY BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 42. FRANCE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 43. FRANCE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 44. SPAIN BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 45. SPAIN BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 46. ITALY BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 47. ITALY BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 48. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 49. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 50. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 52. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2030-2035)
- TABLE 53. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 54. CHINA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 55. CHINA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 56. INDIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 57. INDIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 58. JAPAN BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 59. JAPAN BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 60. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 61. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 62. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 63. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 64. REST OF ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 65. REST OF ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 66. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 68. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2030-2035)
- TABLE 69. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 70. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 71. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 72. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 73. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 74. REST OF MEA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 75. REST OF MEA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 76. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 78. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET BY COUNTRY, (2030-2035)
- TABLE 79. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 80. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 81. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 82. ARGENTINA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 83. ARGENTINA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 84. REST OF LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2022-2029)
- TABLE 85. REST OF LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (USD MILLION) (2030-2035)
- TABLE 86. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 87. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 88. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 89. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 90. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 91. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 92. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 93. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 94. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 95. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 96. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 97. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 98. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 99. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 100. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 101. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 102. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 103. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 104. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 105. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 106. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 107. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 108. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2022-2029)
- TABLE 109. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNIQUE, USD MILLION (2030-2035)
- TABLE 110. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 111. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 112. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 113. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 114. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 115. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 116. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 117. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 118. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 119. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 120. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 121. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 122. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 123. GLOBAL BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 124. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 125. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 126. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 127. EUROPE BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 128. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 129. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 130. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 131. MIDDLE EAST & AFRICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
- TABLE 132. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2022-2029)
- TABLE 133. SOUTH AMERICA BLOOD STREAM INFECTION TESTING MARKET BY BY APPLICATION, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF BLOOD STREAM INFECTION TESTING MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA BLOOD STREAM INFECTION TESTING MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Blood Stream Infection Testing Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 7.11 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 21.7 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 13.2% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Product
By Technique
By Technology
By Application
|
Leading companies covered in this report
- bioMérieux
- Becton Dickinson (BD)
- Roche Diagnostics
- Abbott Laboratories
- T2 Biosystems
- Luminex
- Cepheid (Danaher)
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Blood Stream Infection Testing Market market is expected to grow at a CAGR of 13.2% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 21.7 Billion by 2035.
Key players in the Blood Stream Infection Testing Market include bioMérieux, Becton Dickinson (BD), Roche Diagnostics, Abbott Laboratories, T2 Biosystems, Luminex, and Cepheid (Danaher).
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Blood Stream Infection Testing Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience
Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.
